Biosyngen Pte Ltd announced that the U.S. FDA has cleared the Investigational New Drug application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and other advanced solid tumors.
Biosyngen Pte Ltd announced that the U.S. FDA has cleared the Investigational New Drug application for Phase I/II clinical trial of BRL03 for the treatment of lung cancer, gastric cancer and other advanced solid tumors.